Company / Shareholders' Equity
OCULAR THERAPEUTIX, INC Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$654.3M
FY2025
5-year range
-$3.6M / $654.3M
FY2021-FY2025
Trend
+107.5%
vs FY2024
Sector context
#69 of 213
Health Care
What the data says
At $654M, OCULAR THERAPEUTIX, INC's shareholders' equity ranks #69 of 213 in the Health Care sector. Shareholders' Equity has increased for 4 consecutive years, from -$4M in FY2021 to $654M in FY2025.
Based on SEC 10-K filings.
$654M in FY2025 with a 5-year CAGR of +78.7%.
Improved from $91M to $654M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +104.9%
- 5-Year CAGR
- +78.7%
- 10-Year CAGR
- -
Sector benchmark
#69 of 213 in Health CareTop 32% of 213This company $654.3M Sector average $2.5B
▼
-74.3% below sector average
Key checks
Key Insights
- OCULAR THERAPEUTIX, INC's shareholders' equity has grown for 4 consecutive years.
- 5-year CAGR of +78.7%, indicating consistent growth.
- In FY2025, shareholders' equity increased 107.5% year-over-year.
- Ranks #69 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $654.3M | +107.5% |
| FY2024 | $315.3M | +246.0% |
| FY2023 | $91.1M | +19.8% |
| FY2022 | $76.1M | +2196.3% |
| FY2021 | -$3.6M | -110.1% |
| FY2020 | $35.9M | +0.0% |
| FY2019 | $35.9M | +0.0% |
| FY2018 | $35.9M | +37.2% |
| FY2017 | $26.1M | -49.7% |
| FY2016 | $52.0M | +187.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026